5315992026-04-012026-06-305315992026-04-012026-06-30in-capmkt:OtherExpenses1Member5315992026-04-012026-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15315992026-04-012026-06-30ItemsThatWillBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares531599FDCNOTLISTEDINE258B01022FDC LIMITEDMain BoardEquity2026-04-012027-03-312026-08-052026-07-23INRLakhsQuarterlyFirst quarterSingle segmentPharmaceutical2026-08-0512:30:002026-08-0514:30:00Not applicable2026-04-012026-06-30UnauditedConsolidated6676900000476600000715350000014450000002148000004766000001351600000830000015130000017589000005406500000174700000001747000000397800000243000004221000000132490000000001324900000100000001334900000132490000001334900000016280000018.148.14008.148.141. The above unaudited consolidated financial results which are published in accordance with Regulation 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 (‘Listing Regulations’) for the quarter ended June 30, 2026, have been reviewed by the Audit Committee and approved by the Board of Directors of the Parent Company at their meeting held on August 5, 2026. The Statutory Auditors have carried out a limited review of the above results and have expressed an unmodified review conclusion. <br /> <br /> 2. During the previous year, the Parent Company recognised a fair value loss of Rs. 1,330 lakhs under Other expenses in the quarter ended March 31, 2026 in accordance with Ind AS 109 – ‘Financial Instruments’. However, for the period ended March 31, 2026, a net fair value gain of Rs. 1,179 lakhs was recognised under Other income. Due to this treatment, the quarterly numbers may not be directly additive to the year-to-date (YTD) numbers, as fair value changes are recognised based on market conditions prevailing at different reporting dates. <br /> <br /> 3. During the previous year, the Parent Company recognised an incremental employee benefit obligation of Rs. 2,079 lakhs based on an actuarial valuation in accordance with Ind AS 19 – ‘Employee Benefits‘. The impact was disclosed as an exceptional item in the financial statements for the year ended March 31, 2026, considering its non-recurring nature arising from a regulatory change. The Parent Company continues to monitor further notifications and clarifications issued by the Government and will account for any consequential impact, if required, in the period of such developments. <br /> <br /> 4. During the previous year, the Parent Company had paid an interim dividend of Rs. 5 per equity share of face value Rs. 1 each for the financial year 2025-26, as approved by the Board of Directors of the Parent Company at their meeting held on February 5, 2026. <br /> <br /> 5. The Group has only one segment of activity namely “Pharmaceuticals”. <br /> <br /> 6. Figures for the quarter ended March 31, 2026 are the balancing figures between audited figures in respect of the full financial year ended as on March 31, 2026 and the published year-to-date figures up to end of the third quarter ended as on December 31, 2025 of the relevant financial year. Also, the figures upto the end of third quarter had only been reviewed and not subjected to audit. <br /> <br /> 7. The above results are also available on the website of the Parent Company i.e. www.fdcindia.com and on the website of the Stock Exchanges i.e. www.nseindia.com and www.bseindia.com.Other Expenses1758900000Items that will not be reclassified subsequently to profit or loss17000001700000200000Items that will be reclassified subsequently to profit or loss85000008500000010000000